Capital Research Global Investors Gilead Sciences, Inc. Transaction History
Capital Research Global Investors
- $463 Billion
- Q3 2024
A detailed history of Capital Research Global Investors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 61,799,671 shares of GILD stock, worth $5.77 Billion. This represents 1.12% of its overall portfolio holdings.
Number of Shares
61,799,671
Previous 60,427,714
2.27%
Holding current value
$5.77 Billion
Previous $4.15 Billion
24.94%
% of portfolio
1.12%
Previous 0.94%
Shares
29 transactions
Others Institutions Holding GILD
# of Institutions
1,926Shares Held
992MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$11.3 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.8 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.15 Billion1.03% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.62 Billion0.21% of portfolio
-
Wellington Management Group LLP Boston, MA34.6MShares$3.23 Billion0.52% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $117B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...